GlassScriptPhysician profile
Anil Sharma
NPI 1356393797
$5,775.53
in general payments reported to CMS, 2019-2025
32 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $187 · 2021: $578 · 2022: $974 · 2023: $777 · 2024: $1,565 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,462 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,462.24 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,361.41 | 2020-2025 | Rinvoq, Skyrizi |
| Celgene Corporation | $614.23 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $606.14 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $594.98 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $399.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.63 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Boston Scientific Corporation | $254.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $188.04 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $174.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $145.51 | 2022-2025 | |
| Ardelyx, INC. | $144.37 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $124.25 | 2019-2023 | Dificid |
| Daiichi Sankyo INC. | $87.90 | 2022-2024 | Injectafer |
| Lilly USA, LLC | $87.14 | 2024-2025 | Omvoh |
| Abbott Laboratories | $80.41 | 2024 | Eterna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $74.36 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $66.22 | 2025 | |
| Nestle Healthcare Nutrition INC. | $64.65 | 2021-2022 | |
| Redhill Biopharma INC. | $62.61 | 2021-2023 | |
| Braintree Laboratories, INC. | $44.20 | 2019-2023 | Sutab |
| Qol Medical, LLC | $36.64 | 2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $35.62 | 2024 | |
| Ferring Pharmaceuticals INC. | $31.43 | 2019-2023 | Rebyota |
| Evoke Pharma, INC. | $28.17 | 2024 | |
| Amgen INC. | $27.04 | 2021 | |
| Exact Sciences Corporation | $20.24 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $19.48 | 2024 | Inspire |
| Celltrion USA INC. | $19.41 | 2024 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $17.51 | 2022 | |
| Dova Pharmaceuticals | $15.23 | 2019 | |
| Endo Pharmaceuticals INC. | $11.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.